skip to Main Content

Nab-Paclitaxel Plus Gemcitabine Misses DFS Endpoint in Pancreatic Cancer

Nab-Paclitaxel Plus Gemcitabine Misses DFS Endpoint in Pancreatic Cancer
The adjuvant combination of nab-paclitaxel (Abraxane) and gemcitabine was not found to improve disease-free survival (DFS) compared with gemcitabine alone, as confirmed by independent radiological review, in patients with pancreatic cancer, according to topline findings of the phase III APACT trial (NCT01964430).

However, there was an improvement in overall survival (OS) with the combination versus gemcitabine alone, reaching nominal statistical significance. The safety profile observed was consistent with prior reported studies of nab-paclitaxel. Full findings will be presented at an upcoming medical meeting, stated Celgene, the manufacturer of nab-paclitaxel, in a press release. Read more . . .


Back To Top